MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
227.41
-1.38
-0.60%
After Hours: 227.75 +0.34 +0.15% 19:25 11/28 EST
OPEN
227.65
PREV CLOSE
228.79
HIGH
227.65
LOW
223.89
VOLUME
802.26K
TURNOVER
0
52 WEEK HIGH
319.76
52 WEEK LOW
220.86
MARKET CAP
32.95B
P/E (TTM)
22.62
1D
5D
1M
3M
1Y
5Y
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
Biogen and idec merged in 2003. Biogen has several drug candidates in phase 3 trials in neurology-related fields. The company competes in the biotechnology industry. The stock is undervalued compared to the industry average, and has potential to grow. The industry comparison includes biogen's key competitors.
Benzinga · 22h ago
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)
3 analysts have recently maintained buy ratings on biogen, exact sciences and regeneron. Jefferies maintained a buy rating on regeneron and barclays also maintained a buy rating on the healthcare sector stocks. Biogen and exact sciences are among the top 3 stocks recommended by analysts.
TipRanks · 1d ago
Weekly Report: what happened at BIIB last week (1120-1124)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), Biogen (BIIB)
TipRanks · 6d ago
5 Reasons to Track the Nasdaq-100
NASDAQ · 11/22 14:42
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Clinical trials for at least seven alzheimer's disease vaccines are underway or completed. Recent advances in treatments targeting toxic proteins in the brain have sparked interest in developing vaccines to combat alzheimer's. The vaccines aim to leverage the immune system to eliminate disease-related proteins from the brain. The global alzheimer's population is estimated at 39 million.
Benzinga · 11/21 20:16
Analysts Offer Insights on Healthcare Companies: Agilent (A), Henry Schein (HSIC) and Biogen (BIIB)
Analysts maintain hold ratings on agilent (a – research report), henry schein and biogen today. Stifel nicolaus analyst daniel arias maintained a hold rating on the healthcare sector company. Piper sandler analyst christopher raymond maintained a buy rating on biogen.
TipRanks · 11/21 12:50
Weekly Report: what happened at BIIB last week (1113-1117)?
Weekly Report · 11/20 09:10
More
About BIIB
Biogen Inc. is a global biotechnology company. The Company is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis, spinal muscular atrophy (SMA) and Alzheimer's disease. It is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; FUMADERM for the treatment of severe plaque psoriasis, and SKYCLARYS (omaveloxolone). It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD); BIIB080 for Alzheimer's disease; tofersen for amyotrophic lateral sclerosis (ALS), and both litifilimab and dapirolizumab pegol for certain forms of lupus.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.